调整膳食n-3与n-6脂肪酸减少成人偏头痛:随机对照试验
这项在美国学术医疗中心开展的16周三臂平行组随机改良双盲对照试验纳入182例每月头痛5–20天的偏头痛成人,比较增加EPA+DHA并降低或维持亚油酸的两种膳食与对照膳食。H3-L6与H3膳食均升高血中17-HDHA并减少头痛时数、中重度头痛时数与每月头痛天数,但HIT-6生活质量改善未达统计学显著。
要点
- 增加n-3脂肪酸并降低亚油酸的膳食可减少每月头痛天数,且降亚油酸有额外获益。
- 两种干预膳食均升高血液循环17-HDHA,未改变CGRP和前列腺素E2。
- 头痛影响生活质量问卷HIT-6的改善未达统计学显著。
核心结论
- H3-L6与H3膳食改变了与头痛发病相关的生物活性介质,并减少头痛频率与严重程度,但未显著改善生活质量。
研究设计与样本
- 三臂平行组随机改良双盲对照试验,在美国学术医疗中心门诊开展16周,共182例参与者(88%为女性,平均年龄38岁)。
- 参与者每月偏头痛5–20天,67%符合慢性偏头痛标准;H3组61例、H3-L6组61例、对照组60例。
- H3膳食将EPA+DHA增至1.5 g/天并维持亚油酸约7%能量;H3-L6膳食将EPA+DHA增至1.5 g/天并将亚油酸降至≤1.8%能量;对照膳食维持EPA+DHA<150 mg/天、亚油酸约7%能量。
- 所有参与者获得占每日食物能量三分之二的食品,并继续常规诊疗。
主要发现
- 与对照膳食相比,H3-L6与H3膳食升高循环17-HDHA(log ng/mL),基线校正均值差分别为0.6(95%CI 0.2–0.9)与0.7(95%CI 0.4–1.1)。
- H3-L6与H3组HIT-6评分改善未达统计学显著(分别为-1.6,95%CI -4.2–1.0;-1.5,95%CI -4.2–1.2)。
- 与对照膳食相比,H3-L6与H3膳食减少每日总头痛时数(分别为-1.7,95%CI -2.5至-0.9;-1.3,95%CI -2.1至-0.5)。
- 与对照膳食相比,H3-L6与H3膳食减少每日中重度头痛时数(分别为-0.8,95%CI -1.2至-0.4;-0.7,95%CI -1.1至-0.3)及每月头痛天数(分别为-4.0,95%CI -5.2至-2.7;-2.0,95%CI -3.3至-0.7)。
- H3-L6膳食较H3膳食进一步减少每月头痛天数(-2.0,95%CI -3.2至-0.8),提示降低膳食亚油酸有额外获益。
关键数值与推荐
- 主要终点为第16周血中17-HDHA与头痛影响测试HIT-6(六条目问卷,评估头痛对生活质量的影响)。
- 头痛频率通过电子日记每日评估。
- H3-L6与H3膳食改变血浆、血清、红细胞或免疫细胞中的n-3与n-6脂肪酸及其多种伤害性氧脂衍生物,但未改变经典头痛介质降钙素基因相关肽(CGRP)和前列腺素E2。
- 试验注册号:ClinicalTrials.gov NCT02012790。
临床怎么用
- 对偏头痛成人,可考虑在常规诊疗基础上采用增加EPA+DHA至1.5 g/天并降低亚油酸至≤1.8%能量的膳食模式以减少头痛天数。
- 仅增加n-3脂肪酸而维持亚油酸约7%能量也可减少头痛,但降亚油酸可能带来额外获益。
- 该膳食干预未显著改善HIT-6生活质量评分,应结合个体情况解读其临床意义。
局限性
- HIT-6评分改善未达统计学显著,生活质量获益不明确。
- 参与者88%为女性、平均年龄38岁,结果外推至其他人群需谨慎。
- 为改良双盲设计,膳食干预难以完全盲法,可能影响主观终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether dietary interventions that increase n-3 fatty acids with and without reduction in n-6 linoleic acid can alter circulating lipid mediators implicated in headache pathogenesis, and decrease headache in adults with migraine. DESIGN: Three arm, parallel group, randomized, modified double blind, controlled trial. SETTING: Ambulatory, academic medical center in the United States over 16 weeks. PARTICIPANTS: 182 participants (88% women, mean age 38 years) with migraines on 5-20 days per month (67% met criteria for chronic migraine). INTERVENTIONS: Three diets designed with eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and linoleic acid altered as controlled variables: H3 diet (n=61)-increase EPA+DHA to 1.5 g/day and maintain linoleic acid at around 7% of energy; H3-L6 diet (n=61)-increase n-3 EPA+DHA to 1.5 g/day and decrease linoleic acid to ≤1.8% of energy; control diet (n=60)-maintain EPA+DHA at <150 mg/day and linoleic acid at around 7% of energy. All participants received foods accounting for two thirds of daily food energy and continued usual care. MAIN OUTCOME MEASURES: The primary endpoints (week 16) were the antinociceptive mediator 17-hydroxydocosahexaenoic acid (17-HDHA) in blood and the headache impact test (HIT-6), a six item questionnaire assessing headache impact on quality of life. Headache frequency was assessed daily with an electronic diary. RESULTS: In intention-to-treat analyses (n=182), the H3-L6 and H3 diets increased circulating 17-HDHA (log ng/mL) compared with the control diet (baseline-adjusted mean difference 0.6, 95% confidence interval 0.2 to 0.9; 0.7, 0.4 to 1.1, respectively). The observed improvement in HIT-6 scores in the H3-L6 and H3 groups was not statistically significant (-1.6, -4.2 to 1.0, and -1.5, -4.2 to 1.2, respectively). Compared with the control diet, the H3-L6 and H3 diets decreased total headache hours per day (-1.7, -2.5 to -0.9, and -1.3, -2.1 to -0.5, respectively), moderate to severe headache hours per day (-0.8, -1.2 to -0.4, and -0.7, -1.1 to -0.3, respectively), and headache days per month (-4.0, -5.2 to -2.7, and -2.0, -3.3 to -0.7, respectively). The H3-L6 diet decreased headache days per month more than the H3 diet (-2.0, -3.2 to -0.8), suggesting additional benefit from lowering dietary linoleic acid. The H3-L6 and H3 diets altered n-3 and n-6 fatty acids and several of their nociceptive oxylipin derivatives in plasma, serum, erythrocytes or immune cells, but did not alter classic headache mediators calcitonin gene related peptide and prostaglandin E2. CONCLUSIONS: The H3-L6 and H3 interventions altered bioactive mediators implicated in headache pathogenesis and decreased frequency and severity of headaches, but did not significantly improve quality of life. TRIAL REGISTRATION: ClinicalTrials.gov NCT02012790.
引用
- Ramsden CE, Zamora D, Faurot KR, et al. Dietary alteration of n-3 and n-6 fatty acids for headache reduction in adults with migraine: randomized controlled trial. BMJ. 2021. PMID: 34526307. doi:10.1136/bmj.n1448
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。